 |
|
Disease Course and Prognostic Factors of Progressive Muscular Atrophy
Jeldican Visser, MD;
Renske M. van den Berg-Vos, MD, PhD;
Hessel Franssen, MD, PhD;
Leonard H. van den Berg, MD, PhD;
John H. Wokke, MD, PhD;
J. M. Vianney de Jong, MD, PhD;
Rebecca Holman, PhD;
Rob J. de Haan, PhD;
Marianne de Visser, MD, PhD
Arch Neurol. 2007;64(4):522-528.
Objective To investigate the natural history and prognostic factors in patients with nonhereditary, adult-onset progressive muscular atrophy.
Design Inception cohort conducted for 18 months.
Settings Three university hospitals in the Netherlands (referral centers for neuromuscular diseases).
Patients Thirty-seven consecutive patients newly diagnosed (onset of weakness <4 years) with progressive muscular atrophy enrolled between 1998 and 2001.
Main Outcome Measures Disease progression was measured at 0, 3, 6, 9, 12, 15, and 18 months by the Medical Research Council sum score, number of affected limb regions, and the Amyotrophic Lateral Sclerosis Functional Rating Scale score. Multivariate linear regression analysis was used to identify predictors of poor outcome. Clinical features and classification of phenotype during follow-up were evaluated. Survival analysis was planned after data collection, performed 5 years after the end of the study.
Results Significant decline of muscle strength (mean, 6.01 Medical Research Council sum score points [95% confidence interval [CI], 3.84-8.18]; P value <.001) and significant increase in the number of affected regions (mean, 0.53 affected region [95% CI, 0.42-0.65]; P value <.001) and functional impairment (mean, 1.85 Amyotrophic Lateral Sclerosis Functional Rating Scale score points [95% CI, 1.38-2.33]; P value <.001) were found. Vital capacity (VC) at baseline and decrease of VC during the first 6 months were significantly associated with outcome. Median survival duration after initial weakness was 56 months.
Conclusions This study shows that patients with progressive muscular atrophy have a relentlessly progressive disease course. Patients with a low VC at baseline and a sharp decline of VC during the first 6 months have an especially poor prognosis.
Author Affiliations: Departments of Neurology (Drs Visser, de Jong, and de Visser) and Clinical Epidemiology and Biostatistics (Drs Holman and de Haan), Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Departments of Neurology (Drs van den Berg-Vos, van den Berg, and Wokke) and Clinical Neurophysiology (Dr Franssen), University Medical Center Utrecht, Utrecht, the Netherlands.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
The history of progressive muscular atrophy: Syndrome or disease?
Visser et al.
Neurology 2008;70:723-727.
ABSTRACT
| FULL TEXT
|
